Session Name: Poster Session C: Non-Organ Specific: Economics & Ethics
Date: Saturday, May 30, 2020
Session Time: 3:15pm-4:00pm
Presentation Time: 3:30pm-4:00pm
*Purpose: Immunobiogram (IMBG) is a new IVD bioassay developed by Biohope SL with the aim to support clinicians in the personalized adjustment of immunosuppressive therapy in kidney transplant (KT) recipients. IMBG provides the sensitivity/resistance profile of each patient to a panel of immunosuppressive drugs (IS). The objective was to estimate the economic impact of IMBG use for National-Health-System in Spain.
*Methods: A probabilistic second-order Monte Carlo simulation was applied to a hypothetical cohort of 1,000 patients at least one year after the KT. Two scenarios were considered: graft failure in patients with high-immunological risk (HR) and adverse events (AEs) incidence in stable patients (non-HR). For a time-horizon of 5 years, we assumed one annual IMBG to be performed on HR patients and only one IMBG in total in the follow-up of non-HR patients. The probability of reducing the risk of graft failure by selecting the most effective IS/dose in HR patients with an IMBG resistant profile to the IS they are taking, and the probability of reducing AEs rate due to IS/dose adjustment in non-HR patients with an IMBG sensitive profile were obtained from a clinical study with IMBG and a systematic literature review and validated by a Spanish clinical experts panel. The costs associated with graft failure, IS therapy and AEs management were obtained from Spanish sources.
*Results: IMBG use may entail an estimated risk reduction of graft failure with a saving per HR patient of € 20,279 (95% CI € 17,512-23,105) and a 100% saving probability and an expected reduction in AE rate with savings per non-HR patient of € 3,328 (95% CI € 451-7,957) and a 99.5 saving probability. Considering both populations (HR and non-HR), the savings per patient would be € 7,098 (95% CI € 6,129-8,087), with a 99.7% saving probability.
*Conclusions: Immunobiogram estimated risk reductions of renal graft failure and AEs associated due to a personalized adjustment of immunosuppressive therapy could have considerable savings for the Spanish National-Health-System.
To cite this abstract in AMA style:Rubio C, Jiménez C, Crespo M, Portolés J, Rubio D, Diez T, Portero I. Evaluation of the Economic Impact of a New IVD Immunoassay (Immunobiogram) for Immunosuppressive Treatment Adjustment in Kidney Transplant Recipients in Spain [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/evaluation-of-the-economic-impact-of-a-new-ivd-immunoassay-immunobiogram-for-immunosuppressive-treatment-adjustment-in-kidney-transplant-recipients-in-spain/. Accessed May 6, 2021.
« Back to 2020 American Transplant Congress